SPONSOR
Celgene
Total Trials
5
Recruiting
5
Phases
Phase 2, Phase 3, Phase 2, Phase 3
Conditions studied: AgitationAlzheimer DiseaseMyelodysplastic Syndromes (MDS)Beta-thalassemiaMyeloproliferative Neoplasm(MPN)-Associated MyelofibrosisBeta-ThalassemiaNeoplasmsMultiple Sclerosis Spasticity
NCT06808984 Phase 2
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Agitation
NCT04064060 Phase 3
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Myelodysplastic Syndromes (MDS)
NCT04143724 Phase 2
Recruiting
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Beta-Thalassemia
NCT03435796 Phase 2, Phase 3
Recruiting
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Neoplasms
NCT06782490 Phase 2
Recruiting
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Multiple Sclerosis Spasticity